NDA 219007 · Teva
Weltruza
Olanzapine · Subcutaneous
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Oct 8, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
496
150 Phase 3, 32 recruiting
FAERS reports
69,868
63,963 serious, 9,096 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 , 8.5 )
What it is approved for
From the label in effect Oct 26, 2026.
WELTRUZA is indicated for the treatment of schizophrenia in adults. WELTRUZA is a long-acting atypical antipsychotic for subcutaneous injection indicated for the treatment of schizophrenia in adults. ( 1 )
Mechanism: The mechanism of action of olanzapine, in the listed indications, is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 8, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelMedication Guide
3 products under this application
- WELTRUZA · OLANZAPINE 531MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
- WELTRUZA · OLANZAPINE 318MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
- WELTRUZA · OLANZAPINE 425MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olanzapine" as an intervention, any sponsor and status, largest first.
- Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00418171 · 18,239 participants · Start Feb 2002
Drug: Ziprasidone; Olanzapine · For: Schizophrenia
Sites: San Bernardino, California; ‘Aiea, Hawaii; Schaumburg, Illinois · 5 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Metabolic Profile and Anthropometric Changes in SchizophreniaPivotal-lookingCompleted
Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
NCT00534183 · 2,006 participants · Start Jun 2006
Drug: Olanzapine; Risperidone and 1 more · For: Metabolic Syndrome; Diabetes; Obesity
Sites: Ranchi, India
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
- Treatment of Refractory Nausea and Vomiting in Patients With Breast CancerPivotal-lookingCompleted
University of Rochester NCORP Research BaseAcademic, hospital or other
NCT03367572 · 1,363 participants · Start Apr 19, 2018 · Primary completion Apr 13, 2024
Drug: Dexamethasone; Netupitant/Palonosetron Hydrochloride and 2 more · For: Breast Carcinoma
Sites: Honolulu, Hawaii; Decatur, Illinois; New Orleans, Louisiana · 18 sites in all
- Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00212784 · 1,225 participants · Start Sep 4, 2003 · Primary completion Mar 15, 2006
Drug: asenapine; olanzapine · For: Schizophrenia; Schizoaffective Disorder
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective6,018
- off label use4,340
- toxicity to various agents4,064
- drug interaction3,445
- weight increased2,863
- nausea2,799
- somnolence2,774
- condition aggravated2,404
- fatigue2,383
- vomiting2,382
- suicide attempt2,350
- overdose2,187
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 542 |
| 2005 | 683 |
| 2006 | 537 |
| 2007 | 541 |
| 2008 | 526 |
| 2009 | 685 |
| 2010 | 711 |
| 2011 | 850 |
| 2012 | 1,324 |
| 2013 | 1,411 |
| 2014 | 1,742 |
| 2015 | 2,241 |
| 2016 | 2,617 |
| 2017 | 3,499 |
| 2018 | 4,896 |
| 2019 | 5,508 |
| 2020 | 5,181 |
| 2021 | 5,511 |
| 2022 | 6,270 |
| 2023 | 6,242 |
| 2024 | 6,577 |
| 2025 | 6,754 |
| 2026 | 5,020 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
Sandhya L, Devi Sreenivasan N, Goenka L, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis.
Lü W, Liu F, Zhang Y, et al. · BMJ Ment Health 2024 · Systematic Review, Network Meta-Analysis
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Navari RM, Qin R, Ruddy KJ, et al. · N Engl J Med 2016 · Comparative Study, Randomized Controlled Trial
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.